Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population

Abstract The molecular profile of neurotrophic tyrosine kinase receptor (NTRK) gene fusions in lung adenocarcinoma (LUAD) is not fully understood. Next‐generation sequencing (NGS) and pan‐tyrosine kinase receptor (TRK) immunohistochemistry (IHC) are powerful tools for NTRK fusion detection. In this...

Full description

Bibliographic Details
Main Authors: Ruiying Zhao, Feng Yao, Chan Xiang, Jikai Zhao, Zhanxian Shang, Lianying Guo, Wenjie Ding, Shengji Ma, Anbo Yu, Jinchen Shao, Lei Zhu, Yuchen Han
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:The Journal of Pathology: Clinical Research
Subjects:
Online Access:https://doi.org/10.1002/cjp2.208
_version_ 1831630417317330944
author Ruiying Zhao
Feng Yao
Chan Xiang
Jikai Zhao
Zhanxian Shang
Lianying Guo
Wenjie Ding
Shengji Ma
Anbo Yu
Jinchen Shao
Lei Zhu
Yuchen Han
author_facet Ruiying Zhao
Feng Yao
Chan Xiang
Jikai Zhao
Zhanxian Shang
Lianying Guo
Wenjie Ding
Shengji Ma
Anbo Yu
Jinchen Shao
Lei Zhu
Yuchen Han
author_sort Ruiying Zhao
collection DOAJ
description Abstract The molecular profile of neurotrophic tyrosine kinase receptor (NTRK) gene fusions in lung adenocarcinoma (LUAD) is not fully understood. Next‐generation sequencing (NGS) and pan‐tyrosine kinase receptor (TRK) immunohistochemistry (IHC) are powerful tools for NTRK fusion detection. In this study, a total of 4,619 LUAD formalin‐fixed, paraffin‐embedded tissues were collected from patients who underwent biopsy or resection at the Shanghai Chest Hospital during 2017–2019. All specimens were screened for NTRK1 rearrangements using DNA‐based NGS. Thereafter, the cases with NTRK1 rearrangements and cases negative for common driver mutations were analyzed for NTRK1/2/3 fusions using total nucleic acid (TNA)‐based NGS and pan‐TRK IHC. Overall, four NTRK1/2 fusion events were identified, representing 0.087% of the original sample set. At the DNA level, seven NTRK1 rearrangements were identified, while only two TPM3‐NTRK1 fusions were confirmed on TNA‐based NGS as functional. In addition, two NTRK2 fusions (SQSTM1‐NTRK2 and KIF5B‐NTRK2) were identified by TNA‐based NGS in 350 ‘pan‐negative’ cases. Two patients harboring NTRK1/2 fusions were diagnosed with invasive adenocarcinoma, while the other two were diagnosed with adenocarcinoma in situ and minimally invasive adenocarcinoma. All four samples with NTRK fusions were positive for the expression of pan‐TRK. The two samples with NTRK2 fusions showed cytoplasmic staining alone, while the other two samples with NTRK1 fusions exhibited both cytoplasmic and membranous staining. In summary, functional NTRK fusions are found in early‐stage LUAD; however, they are extremely rare. According to this study's results, they are independent oncogenic drivers, mutually exclusive with other driver mutations. We demonstrated that NTRK rearrangement analysis using a DNA‐based approach should be verified with an RNA‐based assay.
first_indexed 2024-12-19T02:58:25Z
format Article
id doaj.art-e6f3ebc736144f0b819b8f5fd5796e98
institution Directory Open Access Journal
issn 2056-4538
language English
last_indexed 2024-12-19T02:58:25Z
publishDate 2021-07-01
publisher Wiley
record_format Article
series The Journal of Pathology: Clinical Research
spelling doaj.art-e6f3ebc736144f0b819b8f5fd5796e982022-12-21T20:38:16ZengWileyThe Journal of Pathology: Clinical Research2056-45382021-07-017437538410.1002/cjp2.208Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese populationRuiying Zhao0Feng Yao1Chan Xiang2Jikai Zhao3Zhanxian Shang4Lianying Guo5Wenjie Ding6Shengji Ma7Anbo Yu8Jinchen Shao9Lei Zhu10Yuchen Han11Department of Pathology, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai PR ChinaDepartment of Thoracic Surgery, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai PR ChinaDepartment of Pathology, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai PR ChinaDepartment of Pathology, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai PR ChinaDepartment of Pathology, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai PR ChinaDepartment of Pathology, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai PR ChinaDepartment of Pathology, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai PR ChinaDepartment of Pathology, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai PR ChinaDepartment of Pathology, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai PR ChinaDepartment of Pathology, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai PR ChinaDepartment of Pathology, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai PR ChinaDepartment of Pathology, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai PR ChinaAbstract The molecular profile of neurotrophic tyrosine kinase receptor (NTRK) gene fusions in lung adenocarcinoma (LUAD) is not fully understood. Next‐generation sequencing (NGS) and pan‐tyrosine kinase receptor (TRK) immunohistochemistry (IHC) are powerful tools for NTRK fusion detection. In this study, a total of 4,619 LUAD formalin‐fixed, paraffin‐embedded tissues were collected from patients who underwent biopsy or resection at the Shanghai Chest Hospital during 2017–2019. All specimens were screened for NTRK1 rearrangements using DNA‐based NGS. Thereafter, the cases with NTRK1 rearrangements and cases negative for common driver mutations were analyzed for NTRK1/2/3 fusions using total nucleic acid (TNA)‐based NGS and pan‐TRK IHC. Overall, four NTRK1/2 fusion events were identified, representing 0.087% of the original sample set. At the DNA level, seven NTRK1 rearrangements were identified, while only two TPM3‐NTRK1 fusions were confirmed on TNA‐based NGS as functional. In addition, two NTRK2 fusions (SQSTM1‐NTRK2 and KIF5B‐NTRK2) were identified by TNA‐based NGS in 350 ‘pan‐negative’ cases. Two patients harboring NTRK1/2 fusions were diagnosed with invasive adenocarcinoma, while the other two were diagnosed with adenocarcinoma in situ and minimally invasive adenocarcinoma. All four samples with NTRK fusions were positive for the expression of pan‐TRK. The two samples with NTRK2 fusions showed cytoplasmic staining alone, while the other two samples with NTRK1 fusions exhibited both cytoplasmic and membranous staining. In summary, functional NTRK fusions are found in early‐stage LUAD; however, they are extremely rare. According to this study's results, they are independent oncogenic drivers, mutually exclusive with other driver mutations. We demonstrated that NTRK rearrangement analysis using a DNA‐based approach should be verified with an RNA‐based assay.https://doi.org/10.1002/cjp2.208LUADNTRKgene fusionNGSpan‐TRK
spellingShingle Ruiying Zhao
Feng Yao
Chan Xiang
Jikai Zhao
Zhanxian Shang
Lianying Guo
Wenjie Ding
Shengji Ma
Anbo Yu
Jinchen Shao
Lei Zhu
Yuchen Han
Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
The Journal of Pathology: Clinical Research
LUAD
NTRK
gene fusion
NGS
pan‐TRK
title Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
title_full Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
title_fullStr Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
title_full_unstemmed Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
title_short Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
title_sort identification of ntrk gene fusions in lung adenocarcinomas in the chinese population
topic LUAD
NTRK
gene fusion
NGS
pan‐TRK
url https://doi.org/10.1002/cjp2.208
work_keys_str_mv AT ruiyingzhao identificationofntrkgenefusionsinlungadenocarcinomasinthechinesepopulation
AT fengyao identificationofntrkgenefusionsinlungadenocarcinomasinthechinesepopulation
AT chanxiang identificationofntrkgenefusionsinlungadenocarcinomasinthechinesepopulation
AT jikaizhao identificationofntrkgenefusionsinlungadenocarcinomasinthechinesepopulation
AT zhanxianshang identificationofntrkgenefusionsinlungadenocarcinomasinthechinesepopulation
AT lianyingguo identificationofntrkgenefusionsinlungadenocarcinomasinthechinesepopulation
AT wenjieding identificationofntrkgenefusionsinlungadenocarcinomasinthechinesepopulation
AT shengjima identificationofntrkgenefusionsinlungadenocarcinomasinthechinesepopulation
AT anboyu identificationofntrkgenefusionsinlungadenocarcinomasinthechinesepopulation
AT jinchenshao identificationofntrkgenefusionsinlungadenocarcinomasinthechinesepopulation
AT leizhu identificationofntrkgenefusionsinlungadenocarcinomasinthechinesepopulation
AT yuchenhan identificationofntrkgenefusionsinlungadenocarcinomasinthechinesepopulation